Wegovy HD 7.2 mg: Cost, Insurance, and Where to Get It
The FDA approved Wegovy HD (7.2 mg semaglutide injection) on March 19, 2026, and the drug became available at pharmacies nationwide in April 2026. Designed for patients already stabilized on the standard 2.4 mg dose who need additional weight loss, Wegovy HD represents the highest approved dose of semaglutide for chronic weight management. This guide covers everything you need to know about pricing, insurance coverage, pharmacy availability, and how to access the medication.
Where Is Wegovy HD Available?
Wegovy HD launched at over 70,000 US pharmacies in April 2026. Major retail and specialty pharmacy partners include:
- CVS Pharmacy — in-store pickup and mail-order prescription services
- Walgreens — retail locations and digital prescription fulfillment
- Costco Pharmacy — members-only pharmacy with competitive pricing
- NovoCare Pharmacy — Novo Nordisk's direct-to-patient specialty pharmacy with dedicated support team
- Select telehealth providers — virtual consultations with prescription delivery to your door
Novo Nordisk has confirmed that Wegovy HD supply is managed through a separate manufacturing and distribution pipeline from standard Wegovy doses. This means the ongoing supply constraints that previously affected 2.4 mg availability should not impact Wegovy HD at launch. The company has committed to maintaining adequate supply to meet anticipated demand.
How Much Does Wegovy HD Cost?
The list price for Wegovy HD is $1,349.02 per month — identical to the standard Wegovy 2.4 mg formulation. However, what you actually pay depends heavily on your insurance situation:
| Payment Scenario | Monthly Cost | Notes |
|---|---|---|
| Commercial insurance + savings card | $0–$25 | Novo Nordisk savings card required |
| Commercial insurance (no savings card) | $25–$300+ | Depends on plan tier and deductible |
| Self-pay (no insurance) | ~$1,349 | Full list price; savings card cannot be used alone |
| Medicare Part D (after July 2026) | $0–$35 | GLP-1 coverage under IRA expansion |
Insurance Coverage and Savings Programs
Wegovy HD benefits from the same insurance pathways and savings programs as standard Wegovy:
- Novo Nordisk Savings Card: Eligible commercially insured patients can pay as little as $0 per 28-day supply (up to 13 fills). Register at NovoCare.com or through your prescriber's office.
- Prior Authorization: Most insurers require prior authorization for Wegovy HD. Your provider must document that you've been on 2.4 mg for at least 4 weeks and need additional weight loss. If you're already approved for Wegovy 2.4 mg, upgrading to HD is typically classified as a dose escalation, which simplifies the approval process.
- Step Therapy: Some plans require documentation of insufficient weight loss on 2.4 mg before approving the 7.2 mg dose. A weight loss plateau of 3+ months is generally sufficient documentation.
Medicare Coverage: Starting July 2026
Under provisions of the Inflation Reduction Act, GLP-1 receptor agonists including Wegovy HD will be covered by Medicare Part D starting July 1, 2026. This is a landmark expansion that brings these medications within reach for millions of Medicare beneficiaries with obesity. Key details:
- Coverage applies to beneficiaries with a BMI ≥30 (or ≥27 with weight-related comorbidities)
- Standard Part D copays apply — typically $0–$35 per month depending on your plan
- Prior authorization will still be required
- The Novo Nordisk savings card cannot be used with Medicare or Medicaid — this is a federal restriction
If you're on Medicare and interested in Wegovy HD, read our full Medicare GLP-1 coverage guide for detailed eligibility and enrollment information.
Eligibility: Who Qualifies for Wegovy HD?
Wegovy HD is not for new patients. Per the FDA-approved labeling, you must meet these criteria:
- Currently on Wegovy 2.4 mg (or equivalent semaglutide dose) for a minimum of 4 consecutive weeks
- Tolerated the 2.4 mg dose without requiring dose reduction
- Have a clinical need for additional weight loss or improved metabolic parameters
New patients must still begin with the standard titration schedule (0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg) before becoming eligible for the 7.2 mg dose.
Prefer a daily pill? Oral GLP-1 options from $99/mo
Not ready for the higher dose injection? MEDVi offers oral GLP-1 tablets and pills alongside injectables — a provider helps you choose.
See Oral GLP-1 Options →How to Ask Your Doctor About Upgrading
If you're currently on Wegovy 2.4 mg and interested in the higher dose, approach the conversation with data:
- Bring your weight log showing a plateau over 3+ months
- Share any relevant lab results — HbA1c, blood pressure, lipid panel
- Mention specific comorbidities you'd like to address (sleep apnea, type 2 diabetes, joint pain)
- Ask: "I've been on 2.4 mg for [X weeks/months] and my weight loss has stalled. I'd like to discuss whether Wegovy HD 7.2 mg might help me reach my target weight. Can we review my labs and discuss eligibility?"
Medical Disclaimer
Wegovy HD is a prescription medication for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. This article is for informational purposes only and does not constitute medical advice. Pricing and insurance coverage vary by plan and location. Always verify coverage with your insurer and consult your healthcare provider before starting or changing any medication.